Loading…

Practice changing cervical cancer clinical trials

•Cemiplimab treatment is efficacious in patients with recurrent or metastatic cervical cancer (cvx ca).•Pembrolizumab with chemotherapy is active and FDA approved in first line treatment of recurrent/metastatic PDL-1 + cvx ca.•Tisotumab Vedotin (TV) received FDA accelerated approval for treatment of...

Full description

Saved in:
Bibliographic Details
Published in:Gynecologic oncology 2022-06, Vol.165 (3), p.410-412
Main Authors: Pothuri, Bhavana, Eskander, Ramez N., Randall, Leslie M., O'Malley, David M., Slomovitz, Brian, Moore, Kathleen N., Herzog, Thomas J., Coleman, Robert L., Copeland, Larry J., Monk, Bradley J.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Cemiplimab treatment is efficacious in patients with recurrent or metastatic cervical cancer (cvx ca).•Pembrolizumab with chemotherapy is active and FDA approved in first line treatment of recurrent/metastatic PDL-1 + cvx ca.•Tisotumab Vedotin (TV) received FDA accelerated approval for treatment of recurrent/metastatic cvx ca after chemotherapy.•Transformative advances in cvx ca result from collaborations with GOG-P, ENGOT, other global partners and industry sponsors.•Sequencing includes:1) pembrolizumab with first line chemotherapy 2) TV in second line or pembrolizumab if checkpoint naïve.
ISSN:0090-8258
1095-6859
DOI:10.1016/j.ygyno.2022.03.004